

Date 10/03/2026
 Your Ref
 Our Ref 11164

Enquiries to Richard Mutch
 Extension 35687
 Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Answer:

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	43
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	0
1.4 Fulvestrant (fulvestrant or Faslodex)	48
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	37
1.7 Ribociclib (Kisqali)	59
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	14

Headquarters
 Mainpoint
 102 West Port
 Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
 Chief Executive Professor Caroline Hiscox
 Lothian NHS Board is the common
 name of Lothian Health Board

Question:

2. How many patients received the following medicines for **early breast cancer** in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

Answer:

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	30
2.2 Ribociclib (Kisqali)	5 or fewer
2.3 Olaparib (Lynparza)	5 or fewer

Question:

3. How many patients received the following medicines with **curative** treatment intent in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

Answer:

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	31
3.2 Ribociclib (Kisqali)	5 or fewer

Question:

4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Answer:

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	5 or fewer
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	11
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	13

Question:

5. How many patients were treated specifically for breast cancer in the 3 months between the start of October 2025 and the end of December 2025?

Answer:

Type of breast cancer	Number patients treated
5.1 Olaparib - All types of breast cancer	5 or fewer
5.2 Olaparib - Locally advanced or metastatic breast cancer	0
5.3 Talazoparib – All types of breast cancer	0

Question:

6. How many patients were treated in total with the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0
6.2 Pertuzumab with Trastuzumab (Phesgo)	81
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	60
6.4 Trastuzumab Deruxtecan (EnHertu)	29
6.5 Trastuzumab Emtansine (Kadcyla)	16
6.6 Tucatinib (Tukysa)	0
6.7 Neratinib (Nerlynx)	0

Question:

7. How many patients were treated with the following products for a diagnosis of **Breast Cancer** (ICD-10 codes = C50*, D509) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	54
7.2 Trastuzumab Deruxtecan (EnHertu)	28

Question:

8. How many patients received the following products with **curative treatment intent** in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Answer:

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	0
8.2 Pertuzumab with Trastuzumab (Phesgo)	80
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	54
8.4 Trastuzumab Emtansine (Kadcyla)	16

Question:

9. How many patients received the following products as part of **neoadjuvant** or **adjuvant** therapy in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Answer:

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)	0	0	0
9.2 Pertuzumab with Trastuzumab (Phesgo)	33	10	43
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	10	22	32
9.4 Trastuzumab Emtansine (Kadcyla)	0	6	6

Question:

10. How many patients received **trastuzumab deruxtecan (Enhertu)** for the following types of **breast cancer** in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Answer:

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	*Not available – requires linkage

10.2 HER2-**low** Breast Cancer

*Not available – requires linkage

* This information is not held in a centrally extractable format. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients and prescribing over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive